The shares Pharmaceuticals company, specializing in contract research, development, and manufacturing (CRDMO) services in focus following a Bulk deal for Rs. 72.27 crore involving Small Cap World Fund Inc.
Price action
With a market capitalization of Rs. 15,288 crores on Friday, the shares of Sai Life Sciences Limited were down upto 2.8 percent making a low of Rs. 714.00 per share compared to its previous closing price of Rs. 734.30 per share.
What Happened
Sai Life Sciences Limited engaged in contract research, development, and manufacturing (CRDMO) services, recently experienced a bulk deal, in which Small Cap World Fund Inc. bought 10.55 lakh shares consisting of a 0.5 percent stake at Rs. 684.87 apiece on February 20, resulting in a total value of around Rs. 72.27 crore.
About the company
Sai Life Sciences Limited is a global Contract Research, Development, and Manufacturing Organization (CRDMO) specializing in providing services to the pharmaceutical, biotechnology, and life sciences industries. The company offers end-to-end solutions, including drug discovery, development, and manufacturing.
Revenue Segmentation (9MFY25)
The company’s revenue is derived from two segments as follows: CRMO contributes 60 percent, and CRO contributes 40 percent to the overall revenue.
Operational Highlights
The company’s capital expenditure for 9MFY25 was approximately Rs. 300 Cr, and it added 100 KL to its manufacturing capacity in November. The company further expects to add another 100 KL in Q1FY26. Additionally, the company has expanded its Discovery R&D capacity in Hyderabad by increasing lab space for chemistry by 15 percent.
Financials
The company’s total revenue rose by 13.67 percent from Rs. 394.92 crore to Rs. 448.9 crore in Q3FY24-25. Meanwhile, Net profit rose from Rs. 39.61 crore to Rs. 53.85 crore during the same period.
Written by Sridhar J
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
